Evaluation of Serum Level of Claudin‐ 3 and Its Association with Disease Severity in Patients with Psoriasis in Iraqi patients

Abstract

Background Psoriasis is a prevalent inflammatory skin disease. Psoriasis is a complex illness in which environmental variables acting on individuals with unique genetic predisposition causing immunological dysregulation. Claudins are transmembrane proteins that help to generate tight junctions by binding to the actin cytoskeleton. Claudin 3 in the blood is thought to be a good indicator of intestinal permeability. Objective: The aim of this study was to detect of the alteration of claudin-3 in psoriasis patient and find the correlation between severity and concentration of the claudin-3. Patients and methods: forty psoriatic patients (25males and 15 females) and thirty normal healthy controls (19 men and 11 females) who were age and sex matched to the cases group were included in this study. They were chosen at random from Al Fallujah hospital Dermatology Department outpatient clinic. Result: When compared to the control group, the psoriasis group had substantially greater levels of claudin-3 (mean=2.18 ± 0.16 versus 1.27 ± 0.03; p0.0001). Furthermore, the amount of claudin-3 rose progressively as the severity grade increased (001). There were no significant correlations between claudin-3 levels and gender, dietary status, or family history in the psoriasis group (p>0.05 for each). Conclusion: Claudin-3 levels were considerably greater in psoriasis patients than in healthy controls. PASI levels were shown to be linked to claudin-3 levels.

Evaluation of Some Intestinal Biomarkers in the Determination of Intestinal Damage in Calves with Coccidiosis

“…In the present study, serum CLD-3 level was significantly higher than the control group before treatment (0 th hours) (Table 3, Figure 1D). We believe that the potential cause of the rise before therapy may be connected to the rise in CLD-3 release as a preventative measure to reinforce the intestinal tight junctions during the early stage of intestinal injury, as reported by other researchers (Sikora et al, 2019;Ahmed et al, 2021). In addition, there are positive correlations between CLD-3 and I-FABP (p<0.01), IL-8 (p<0.05), ACTG2 (p<0.01), and IAP (p<0.05) levels (Table 4) showing that these biomarkers have essential relationships between the body's inflammatory response, damage, and repair to the pathological condition in the intestines due to different causes.…”

“…Zeissig et al (2007) reported that CLD-3 concentration was lower in people with Crohn's disease, indicating intestinal barrier dysfunction. However, it has been reported that CLD-3 level is higher in Psoriasis patients than in healthy people (Sikora et al, 2019;Ahmed et al, 2021), CLD-2 and CLD-3 levels are significantly increased in Celiac patients (Adriaanse et al, 2017). It has been reported that CLD -3 concentrations are lower in premature calves with respiratory distress syndrome (Yıldız et al, 2019) and calves with neonatal diarrhoea (Ok et al, 2020) than in healthy calves.…”

“…It has also been reported that Claudin-3 release is severely reduced in people with inflammatory bowel disease (Zeissig et al, 2007). Claudin-3 levels are elevated in patients with psoriasis and have been considered to indicate intestinal barrier malfunction and damage (Sikora et al, 2019;Ahmed et al, 2021). It has been reported that Claudin-3 levels are lower in calves with neonatal enteritis (Ok et al, 2020) and respiratory distress syndrome (Yildiz et al, 2019) compared to healthy ones.…”